Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346711 | 0.98 | TDP1 (0.41) | SIGMAR1TDP1CYP3A4MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL1465772 | 0.98 | SIGMAR1 (0.38) | SIGMAR1TDP1CYP3A4MEN1KMT2A | |
| SCHEMBL31026596 | 0.98 | SIGMAR1 (0.38) | SIGMAR1TDP1CYP3A4MEN1KMT2A | |
| SCHEMBL1465693 | 0.93 | SIGMAR1 (0.35) | SIGMAR1TDP1CYP3A4MEN1KMT2A | |
| SCHEMBL19265778 | 0.91 | SIGMAR1 (0.43) | SIGMAR1CHRM2DRD2DRD4DRD3 | |
| SCHEMBL20706230 | 0.89 | SMN1; SMN2 (0.43) | GAA | |
| Carbon Monoxide SCHEMBL31488742 | 0.89 | SIGMAR1 (0.33) | SIGMAR1TDP1CYP3A4MEN1KMT2A | |
| SCHEMBL19933254 | 0.89 | SIGMAR1 (0.39) | SIGMAR1TDP1CYP3A4MEN1KMT2A | |
| SCHEMBL18216551 | 0.89 | HDAC3 (0.33) | SIGMAR1TDP1CYP3A4MEN1KMT2A | |
| Carbon Monoxide SCHEMBL30049536 | 0.88 | SIGMAR1 (0.32) | SIGMAR1TDP1CYP3A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574508-A | Insulating oligomer film material | 珠海昊天机电科技有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-120202228-A | Method for preparing polyolefin by cascade polymerization | 浙江大学衢州研究院 | 2025-06-24 | — | — | CN | claimed |
| WO-2025000320-A1 | METHOD FOR PREPARING POLYOLEFIN BY MEANS OF CASCADE POLYMERIZATION | 浙江大学衢州研究院 | 2025-01-02 | — | — | WO | claimed |
| CN-117917412-A | Process for preparing chiral lactones | 帝斯曼知识产权资产管理有限公司 | 2024-04-23 | — | — | CN | claimed |
| CN-109867771-B | Preparation method of low-extraction high-temperature-resistant insulating polyester film | 佛山杜邦鸿基薄膜有限公司 | 2020-12-08 | — | — | CN | claimed |
| CN-109867771-A | It is a kind of it is low extraction, high-temperature insulation polyester film preparation method | 佛山杜邦鸿基薄膜有限公司 | 2019-06-11 | — | — | CN | claimed |
| EP-1456153-B1 | TRIMERISATION AND OLIGOMERISATION OF OLEFINS USING A CHROMIUM BASED CATALYST | SASOL TECH PTY LTD (ZA) | 2012-06-13 | — | — | EP | claimed |
| JP-4266827-B2 | — | — | 2009-05-20 | — | — | JP | claimed |
| US-7361623-B2 | Trimerisation and oligomerisation of olefins using a chromium based catalyst | SASOL TECHNOLOGY (PTY) LTD. (ZA) | 2008-04-22 | — | — | US | claimed |
| WO-2006123343-A2 | BIOLOGICALLY ACTIVE METAL-COATED PROTEINS | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2006-11-23 | — | — | WO | claimed |
| EP-1307239-A4 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2005-01-26 | — | — | EP | claimed |
| EP-1456153-A1 | TRIMERISATION AND OLIGOMERISATION OF OLEFINS USING A CHROMIUM BASED CATALYST | Sasol Technology (Pty) Ltd (ZA) | 2004-09-15 | — | — | EP | claimed |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2004-01-29 | — | — | US | claimed |
| WO-2003053891-A1 | TRIMERISATION AND OLIGOMERISATION OF OLEFINS USING A CHROMIUM BASED CATALYST | SASOL TECHNOLOGY (PTY) LTD. (ZA) | 2003-07-03 | — | — | WO | claimed |
| EP-0949265-B1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | NIHON MEDIPHYSICS CO LTD (JP) | 2003-05-07 | — | — | EP | claimed |
| EP-1307239-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 2003-05-07 | — | — | EP | claimed |
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | DUATTI ADRIANO (IT) | 2002-04-25 | — | — | US | claimed |
| WO-2002009771-A1 | RADIOPHARMACEUTICAL FOR DIAGNOSTIC IMAGING CONTAINING A TECHNETIUM-99M NITRIDE HETEROCOMPLEX | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2002-02-07 | — | — | WO | claimed |
| US-6270745-B1 | FROM A BIS(PHOSPHINOALKYL) SULFIDE OR AMINE | NIHON MEDI-PHYSICS CO., LTD. (JP) | 2001-08-07 | — | — | US | claimed |
| EP-0949265-A1 | RADIOACTIVE TRANSITION METAL NITRIDE HETERO-COMPLEX | Nihon Medi-Physics Co., Ltd. (JP) | 1999-10-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020048549-A1 | Radioactive transition metal nitride heterocomplex | SHBG, GNRHR, PRMT5 | SIGMAR1 880/4885TDP1 1924/4885CYP3A4 2456/4885 |
| US-20040018147-A1 | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | SHBG, TNNT2, TNNI3 | SIGMAR1 899/4885TDP1 852/4885CYP3A4 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.